Objectives: Crohn's disease (CD) and Behçet's disease (BD) are two autoinflammatory diseases that share clinical and pathogenic features. Furthermore, when BD involves the gastrointestinal tract, it is extremely difficult to distinguish endoscopic lesions from CD lesions. HLA-B*51 allele expression is highly associated with BD diagnosis. In this study we analysed HLA-B*51 status in 70 Argentine patients with confirmed CD diagnosis and compared it to our previous Argentine BD cohort, with the aim of finding similarities or differences between these two diseases regarding HLA-B*51 status.
Methods: This is a multi-centre case-control study, including 70 patients with confirmed CD diagnosis, who underwent HLA-B*51 allele status testing; the results were compared to our previous BD cohort of 34 patients.
Results: Among patients with CD, 12.85% were positive for the HLA-B*51 allele, compared with 38.24% patients with BD (OR=0.238; 95% CI=0.089-0.637; p=0.004).
Conclusions: Our finding suggests that determination of HLA-B*51 allele status may contribute to the differential diagnosis between CD and BD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.55563/clinexprheumatol/yr9c5h | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Behçet's disease and factor V Leiden: A thrombogenic synergy causing budd-chiari syndrome.
Radiol Case Rep
February 2025
Department of Internal Medicine, An Najah National University Hospital, Nablus, Palestine.
Behçet's Disease (BD) is a multisystem inflammatory disorder that can lead to severe vascular complications, including Budd-Chiari Syndrome (BCS), a rare but life-threatening condition characterized by hepatic vein obstruction. The co-occurrence of BD and inherited thrombophilia, such as Factor V Leiden mutation, significantly increases the risk of thrombosis, complicating the clinical management of affected individuals. In this case, a 16-year-old female initially presented with nonspecific symptoms of generalized fatigue and bone pain, which later progressed to abdominal distension and significant hepatosplenomegaly.
View Article and Find Full Text PDFCharacterisation of the Novel HLA-B*51:409N Allele by Next-Generation Sequencing.
HLA
December 2024
Department Histocompatibility, Amiens University Medical Centre, Amiens, France.
HLA-B*51:409N differs from the HLA-B*51:01:01:01 by one nucleotide at position 923 in exon 3.
View Article and Find Full Text PDFThe HLA-B*51:377N Allele Identified in a Volunteer Donor for Haematopoietic Stem Cell Transplant.
HLA
November 2024
Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
HLA-B*51:377N differs from HLA-B*51:01:01:01 in codon 13 in exon 2.
View Article and Find Full Text PDFHLA-B*51:01 in Iranian patients with Behcet uveitis syndrome.
Reumatol Clin (Engl Ed)
November 2024
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Background: Behcet's disease (BD) is a multisystem disorder prevalent along the historic Silk Road, with Behcet's uveitis (BU) representing a significant complication contributing to disability. Various studies have linked different HLA alleles with BD across diverse populations.
Methods: In this study, we investigated the association between HLA-B51:01/x and HLA-B27/x genotypes with Behcet's uveitis in 50 unrelated Iranian patients diagnosed with Behcet's uveitis, comparing them to a control group of 70 healthy individuals.
Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity.
J Allergy Clin Immunol Pract
January 2025
Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Linkou, Taipei, and Keelung, Taiwan; Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen, China; Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan; Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China; Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao-tong University, Shanghai, China; Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan. Electronic address:
Article Synopsis
- - Osimertinib is an effective lung cancer drug, but it can cause severe allergic reactions, especially in Asian patients, which can complicate treatment.
- - A study of 17 patients showed that the genetic marker HLA-B*51:02 was found in a high percentage of those experiencing severe allergic reactions (SJS/TEN), indicating a strong genetic predisposition.
- - The presence of HLA-B*51:02 also correlated with higher levels of a specific protein related to these reactions, suggesting that individuals with this genetic marker may be at risk for severe side effects when taking osimertinib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!